ReviewBrain pathology (Zurich, Switzerland)2021
Focal cortical dysplasia type 1.
Review in Brain pathology (Zurich, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 21 citations in OpenAlex.
- Asparagine Synthetase Deficiency: Neuropathological Evidence of Disrupted Cortical Development.JIMD reports · 2026Article
- Characteristics and long-term outcomes of children with confirmed focal cortical dysplasia type 1 after epilepsy surgery: A population-based study.Epilepsia open · 2026Article
- Duration-dependent hippocampal structural changes in focal epilepsy: multicenter neuroimaging evidence.Journal of translational medicine · 2026Article
- Excitatory neurons and astrocytes-specific dysregulation and aberrant interactions are vulnerable to FCDI as suggested by single-cell spatial transcriptomics.Clinical and translational medicine · 2026Article
- Radiogenomics of congenital brain malformations: Linking embryology, genetics, and imaging.Neuroradiology · 2026Review
- Microstructural spine alterations increase neuronal excitability in focal cortical dysplasia Type I.Frontiers in computational neuroscience · 2026Article
- Malformations of cortical development: Embryology and epilepsy.Epilepsia · 2025Review
- A new perspective on drug-resistant epilepsy in children with focal cortical dysplasia type 1: From challenge to favorable outcome.Epilepsia · 2025Article
- Hypometabolic patterns are related to post-surgical seizure outcomes in focal cortical dysplasia: A semi-quantitative study.Epilepsia open · 2024Article
- Between neurons and networks: investigating mesoscale brain connectivity in neurological and psychiatric disorders.Frontiers in neuroscience · 2024Review
- The alteration of cortical microstructure similarity in drug-resistant epilepsy correlated with mTOR pathway genes.EBioMedicine · 2023Article
- Diagnostic Accuracy of Epilepsy-dedicated MRI with Post-processing.Clinical neuroradiology · 2023Article
- The specific DNA methylation landscape in focal cortical dysplasia ILAE type 3D.Acta neuropathologica communications · 2023Article
- An Assessment of the Pathological Classification and Postoperative Outcome of Focal Cortical Dysplasia by Simultaneous Hybrid PET/MRI.Brain sciences · 2023Article
- Multimodal imaging-based diagnostic approach for MRI-negative posterior cortex epilepsy.Therapeutic advances in neurological disorders · 2023Article
- Article
- MRI of focal cortical dysplasia.Neuroradiology · 2022Review
- An introduction to the mini-symposium on "The Neuropathology of Focal Human Epilepsy".Brain pathology (Zurich, Switzerland) · 2021Article
- Current Review in Basic Science: Animal Models of Focal Cortical Dysplasia and Epilepsy.Epilepsy currentsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ILAE classification of Focal Cortical Dysplasia (FCD) from 2011 has quickly gained acceptance in clinical practice and research and is now widely used around the world. This histopathology-based classification scheme proposed three subtypes, that is, FCD Type 1 (with architectural abnormalities of the neocortex), FCD Type 2 (with cytoarchitectural abnormalities of the neocortex) and FCD Type 3 (architectural abnormalities of the neocortex associated with another principle lesion acquired during early life). Valuable knowledge was gathered during the last decade validating the clinical, pathological and genetic classification of FCD Type 2. This is in contrast to FCD subtype 1 and 3 with only few robust or new insights. Herein, we provide an overview about current knowledge about FCD Type 1 and its three subtypes. Available data strengthened, however, FCD Type 1A in particular, whereas a comprehensive clinico-pathological specification for FCD Type 1B and 1C subtypes remain to be shown. The lack of a valid animal model for FCD Type 1 further supports our call and the ongoing need for systematic research studies based on a careful clinico-pathological and genetic stratification of patients and human brain tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.